Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64ec17923c8e6bda84be402519213e5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39a154ae2a5a028a6cc24bbea098eb69 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4747 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
filingDate |
2008-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9426ee3e48f4a27723f504646fd11c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94eb5697fb7aff94c26eb2497d1efb0a |
publicationDate |
2008-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2008261883-A1 |
titleOfInvention |
Runx3 gene showing anti-tumor activity and use thereof |
abstract |
The present invention relates to a RUNX3 gene showing anti-tumor activity which is essentially involved in TGF-β-dependent programmed cell death (apoptosis) and use thereof. In addition, the present invention finds that RUNX3 gene expression is suppressed in the various gastric cancer and lung cancer cell lines. The suppression of the RUNX3 gene expression is due to hyper-methylation of CpG islands located around RUNX3 exon 1. The RUNX3 gene and its gene product of the present invention can be used effectively for the development of anti-cancer agents. The CpG islands around RUNX3 exon 1 could also be used not only for the development of anti-cancer agents which regulate the abnormal DNA methylation and thereby induce RUNX3 expression, and also for the development of methods for cancer diagnosis by measuring the abnormal DNA methylation. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11235001-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021330740-A1 |
priorityDate |
2001-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |